Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.25) by 88 percent. This is a 88.46 percent increase over losses of $(0.26) per share from the same period last year.
Reported Sunday, Energy Fuels Inks Definitive Scheme Implementation Deed With Base Resources For The Acquisition Of All Issued Shares For ~A$375M
The acquisition will include Base Resources' 100%-owned advanced, world-class Toliara heavy mineral sands project in Madagascar ("Toliara" or the "Project"), which includes a
